A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-23
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety,
tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors. This
study is divided into 3 periods: dose escalation period, dose expansion period, and clinical
expansion period.